

CHEMICALS



INDUSTRIES

INTEROFFICE LAKE CHARLES

7/22/86

TO

Distribution

DATE

July 22, 1986

FROM

J. Murry Davis

SUBJECT

Restrictions From Derivatives
Due to Abnormal Blood
Chemistries

On Friday, July 11, 1986, a meeting was held in the E. R. Conference Room with the following people present to discuss the above subject: J. C. Delgado, Manager of Industrial Health & Hygiene, Chemicals; John Fike, Manager, Derivatives, Lake Charles; Chuck Bellon, Director of Employee Relations, Lake Charles; Dr. Robert C. Looney, Plant Physician, Lake Charles; and the writer. After a review of the Federal Vinyl Chloride Standards and the PPG Guidelines, the group agreed to the following policies and procedures for the Lake Charles Plant.

1. Employees working in the Vinyl II and Tri-II Plants will be monitored according to the Federal Vinyl Chloride Standards. If lab analysis reveals an abnormality of any one of the designated liver enzyme tests the employee will be retested within three weeks. If the abnormality persists, he/she will be removed from the area of potential exposure and monitored on three month intervals until all five enzymes are within the normal range. When this occurs, the Plant Physician will approve the individual to return to his/her regular job duties. If the abnormalities persist and there is no known causes for the condition, the employee may be subjected to further studies by a doctor of internal medicine or a hepatologist to determine if there is an underlying cause that would prohibit the individual from potential exposure to vinyl chloride or any other derivative in the area. If the physician does not feel the abnormality should prohibit the individual's return to the area of potential exposure a written report will be submitted by him and the person will be returned to his/her normal duty. The Plant Medical Department will schedule the individual for followup blood work at six month intervals or sooner if so designated by the physician. *(max. of 4 evals recommended by the doctor under the div. of on actual Consultant referred consulting will cont. be monitored as the health care policy)*
2. Employees assigned to work in other areas of the Derivatives operation will also be monitored on an annual basis. When any two of the five liver enzyme tests are abnormal, he/she will be retested in three weeks. If the abnormality persists the individual will be removed from the area and monitored at three month intervals until such time as the condition returns to normal. If the abnormality persists, the individual will receive the same considerations as explained in the preceding discussion. If there is only one liver enzyme out of the normal range, the Plant Physician will use a designated calculation as follows: Ten percent of the abnormal range plus one standard deviation as prescribed by the medical laboratory performing the analysis. Based on this calculations, the Plant Physician will determine if the abnormality is within an acceptable range or not. If not, then the

SL 048730

individual will be subjected to the same procedure as outlined in the above discussion.

3. An employee will be allowed to be restricted and return to the derivatives area only two times. If the restriction occurs a third time, he/she shall be permanently removed and not allowed to return. Any employee restricted will be notified of this policy and will be counseled accordingly.
4. These policies and procedures shall be consistently administered to all employees who may be monitored for work in the derivatives area.

Distribution:

John Fike
Chuck Bellon
J. D. Delgado
Bob Moss

RJM/fb